Overview

A Study in Healthy Men to Compare 2 Different Formulations of Alteplase

Status:
Completed
Trial end date:
2021-06-21
Target enrollment:
Participant gender:
Summary
To establish the bioequivalence of alteplase derived from two different manufacturing processes.
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Calcium heparin
Heparin
Tissue Plasminogen Activator